Clinical trial

Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

NCT00265551

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2006-01-01

PhasePHASE2

Study timeline

Study start (unknown)2006-01-01Date precision: month

Registry last updated2007-12-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Interventions

SCA-136 (200 mg)DRUG

SCA-136 (400 mg)DRUG

olanzapine (15 mg)DRUG

placeboDRUG

Sponsors & collaborators

Wyeth is now a wholly owned subsidiary of Pfizerlead sponsor

Mapped research locations

CincinnatiOhio, United States2 San DiegoCalifornia, United States2 AustinTexas, United States2 BaltimoreMaryland, United States1 St LouisMissouri, United States1 Washington D.C.District of Columbia, United States1 IndianapolisIndiana, United States1 Oklahoma CityOklahoma, United States1 MemphisTennessee, United States1 Little RockArkansas, United States1 Fort LauderdaleFlorida, United States1 TacomaWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00265551 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.